Genomics

Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
ACT, Cancer, COVID, Growth, History, Clinical trial, Genomics, Bookkeeping

HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates.

Key Points: 
  • HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced unaudited financial results for the fourth quarter and full year ended December 31, 2023, along with recent business updates.
  • Revenue from continuing operations of US$5.4 million in the fourth quarter 2023, an increase of 90.8% as compared to the fourth quarter 2022.
  • Adjusted EBITDA from continuing operations of US$(6.2) million in the fourth quarter 2023.
  • Adjusted net loss attributable to equity shareholders of Prenetics was US$(28.4) million for the year ended December 31, 2023.

S2 Genomics Announces Groundbreaking Single Cell FFPE Sample Prep Isolation Product

Retrieved on: 
Tuesday, April 9, 2024
Chemicals, Plastics, Electronic Design Automation, Manufacturing, Technology, Stem Cells, Pharmaceutical, Oncology, Medical Devices, Genetics, Clinical Trials, Other Manufacturing, Other Technology, Biotechnology, Science, Research, Health, Genomics, Tissue, RNA, The central science, Antibiotics

S2 Genomics, a pioneer in tissue sample preparation systems, today announced the launch of its latest product, the Singulator™ 200+ System, an automated sample prep isolation system for single cell formalin-fixed, paraffin-embedded (FFPE) tissues.

Key Points: 
  • S2 Genomics, a pioneer in tissue sample preparation systems, today announced the launch of its latest product, the Singulator™ 200+ System, an automated sample prep isolation system for single cell formalin-fixed, paraffin-embedded (FFPE) tissues.
  • The new FFPE sample prep isolation system is designed to isolate nuclei from FFPE tissue slices, enabling single-nucleus RNA sequencing (snRNA-Seq) for FFPE samples.
  • Jonathan Schimmel, President and CEO of S2 Genomics, expressed his enthusiasm for the new product: “The FFPE sample prep isolation system is a testament to our commitment to continuing innovation and excellence in the field of single cell genomics.
  • For more information about the FFPE sample prep isolation system and other S2 Genomics products, please visit us at s2genomics.com or connect with us on LinkedIn or Twitter .

Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

Retrieved on: 
Tuesday, April 9, 2024
Cardiology, Biotechnology, Technology, Health, General Health, Pharmaceutical, Health Technology, Other Technology, Medical Devices, Artificial Intelligence, Genetics, Diagnosis, Exponential, Cardio, Genomics, Cardiovascular disease, Growth, Entrepreneurship, Partnership, Risk, Patient, Artificial intelligence, Splenic infarction, Death, CHD, Medicine, Concierge medicine, Epigenomics, Moyamoya disease, USD, Medical device

As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.

Key Points: 
  • As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.
  • Concierge practices such as Exponential Health are leading the way in adopting epigenetic cardiovascular solutions.
  • "We are thrilled to partner with Dr. Baer and Exponential Health," said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics.
  • Integrating Cardio Diagnostics' advanced tests into Exponential Health's offerings is a proactive step toward mitigating this global health challenge.

CancerIQ CEO Feyi Ayodele Named to Modern Healthcare’s 2024 Innovators List

Retrieved on: 
Tuesday, April 9, 2024
Oncology, Health, Technology, Hospitals, Genetics, Software, Genomics, Organization, Genetic testing, Risk, Patient, Mortality, AI, Risk assessment, Moonshot, Breast cancer, Multimedia, Pharmaceutical industry

CancerIQ is proud to announce that co-founder and CEO Feyi Ayodele was recognized by Modern Healthcare as one of the Innovators for 2024 expanding access to genetically informed cancer prevention, early detection and treatment.

Key Points: 
  • CancerIQ is proud to announce that co-founder and CEO Feyi Ayodele was recognized by Modern Healthcare as one of the Innovators for 2024 expanding access to genetically informed cancer prevention, early detection and treatment.
  • The profiles of the honorees are featured in the April 8, 2024 issue of MH magazine and online at ModernHealthcare.com/Innovator-Awards .
  • “The role of innovation has always been paramount in healthcare, and our 2024 honorees as top Innovators are driving real change in the industry,” said Mary Ellen Podmolik, editor in chief of Modern Healthcare.
  • She has driven adoption of the platform across 225 diverse clinical locations and specialties to make a direct patient impact.

International Weed Genomics Consortium Celebrates Three Years of Achievements

Retrieved on: 
Tuesday, April 9, 2024
FFAR, Genomics, Gene, Organization, Farmer, Database, BASF, International, Knowledge, WSSA, Science policy, Science, Weed control, Genome, Plant, Doctor of Philosophy, Michigan State University, Herbicide, Colorado State University, Policy, IWGC, Food, Agriculture

WESTMINSTER, Colo., April 9, 2024 /PRNewswire-PRWeb/ -- Since its founding in April, 2021, the International Weed Genomics Consortium (IWGC) has been steadily advancing weed science via collaboration. These advancements include weed species genome sequencing, assembly, and annotation that are accessible via the IWGC weed species website, WeedPedia, and other collaborative databases. Additionally, IWGC offers multiple conferences and training opportunities to share its findings with others each year.

Key Points: 
  • Since its founding in April, 2021, the International Weed Genomics Consortium (IWGC) has been steadily advancing weed science via collaboration.
  • These advancements include weed species genome sequencing, assembly, and annotation that are accessible via the IWGC weed species website, WeedPedia, and other collaborative databases.
  • WESTMINSTER, Colo., April 9, 2024 /PRNewswire-PRWeb/ -- Since its founding in April, 2021, the International Weed Genomics Consortium (IWGC) has been steadily advancing weed science via collaboration.
  • These advancements include weed species genome sequencing, assembly, and annotation that are accessible via the IWGC weed species website , WeedPedia , and other collaborative databases.

Dovetail Genomics Introduces Novel LinkPrep™ NGS Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Genetic variation, Gene, Genetics, Patient, NGS, 3D, Chromatin, Cancer, Genome, Workflow, Genomics, Poster, Chromosomal translocation, Mobile phone

BOSTON, April 9, 2024 /PRNewswire/ -- Dovetail Genomics today announces the debut of its LinkPrep™ NGS technology, showcasing its potential for de novo detection of structural variants and chromatin topology features in cancer. Through its innovative chromatin conformation approach, LinkPrep™ technology exhibits enhanced sensitivity in detecting translocations and intra-chromosomal rearrangements compared to conventional methods, while also identifying SNVs/InDels within a single assay. Unlike traditional Hi-C methods, LinkPrep technology offers a streamlined process, generating sequenceable libraries from initial samples in a single shift. These findings are being presented at the AACR Annual Meeting, April 5-10, in San Diego, Calif.

Key Points: 
  • Unlike traditional Hi-C methods, LinkPrep technology offers a streamlined process, generating sequenceable libraries from initial samples in a single shift.
  • These findings are being presented at the AACR Annual Meeting, April 5-10, in San Diego, Calif.
  • This will improve the discovery and annotation of novel drivers and mechanisms of cancer.
  • Currently undergoing late-stage validation, Dovetail Genomics is actively seeking strategic partnerships to conduct further studies demonstrating its clinical utility across specific cancer indications.

Scispot Joins Ontario Genomics' BioCreate Program to Enhance Ontario's Role on the Global Biomanufacturing Stage

Retrieved on: 
Friday, April 5, 2024
Health, Organization, Growth, Agriculture, OCI, University, Food, Ontario Genomics, Genomics, CIX

KITCHENER, ON, April 5, 2024 /PRNewswire-PRWeb/ -- Scispot, the leading tech stack for biotech, announced its selection into the BioCreate Program by Ontario Genomics. This selection underscores its innovative efforts in creating AI-powered digital infrastructure to bolster the bioeconomy in Canada and worldwide.

Key Points: 
  • KITCHENER, ON, April 5, 2024 /PRNewswire-PRWeb/ -- Scispot , the leading tech stack for biotech, announced its selection into the BioCreate Program by Ontario Genomics.
  • This selection underscores its innovative efforts in creating AI-powered digital infrastructure to bolster the bioeconomy in Canada and worldwide.
  • "Being selected for the BioCreate program is a privilege, allowing us to contribute to Ontario's expanding biotech influence.
  • For more information about Scispot's role in transforming the biotech sector, visit Scispot

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

Retrieved on: 
Monday, March 25, 2024
Survival, Verge, ALS, Caregiver, Social justice, Partnership, Patient, SAN, Tissue, News, Business development, Ferrer, POC, Neuron, B Corporation (certification), Clinical trial, Genomics, DSM-IV codes, Drug development, Safety, CONVERGE, Pharmaceutical industry

VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.

Key Points: 
  • VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.
  • Under the terms of the agreement, Ferrer will obtain the exclusive rights to co-develop and commercialize VRG50635 for ALS in multiple regions outside of the United States of America.
  • Verge has retained all rights to development and commercialization for VRG50635 for all uses in the United States and all countries outside the agreement.
  • “We're thrilled to work with Ferrer to progress VRG50635 through clinical development and towards potential commercialization.

Gattaca Genomics Welcomes Dr. Gary Harton as Principal Scientific Advisor

Retrieved on: 
Thursday, March 21, 2024
Health, Genetic testing, Entrepreneurship, Biotechnology, Genetics, University, Doctor of Philosophy, Genomics

Florida, March 21, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics , a leader in reproductive health and genetic testing services, is proud to announce the appointment of Dr. Gary L. Harton, PhD, as a consultant and Principal Scientific Advisor.

Key Points: 
  • Florida, March 21, 2024 (GLOBE NEWSWIRE) -- Gattaca Genomics , a leader in reproductive health and genetic testing services, is proud to announce the appointment of Dr. Gary L. Harton, PhD, as a consultant and Principal Scientific Advisor.
  • Gary Harton, with a PhD from the University of Kent and a distinguished career spanning several leading genetics and reproductive health organizations, has joined Gattaca Genomics to enhance the company's scientific and research endeavours.
  • ", says Dr. Harton
    "We are incredibly fortunate to have Dr. Gary Harton join our team as a consultant and Principal Scientific Advisor.
  • “The entire Gattaca Genomics team looks forward to working with Dr. Harton and benefiting from his expertise and leadership.”

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Retrieved on: 
Tuesday, March 19, 2024
Ovarian cancer, DNA repair, Breast, SAN, Neoplasm, DNA, HBOC, Doctor of Philosophy, Medicine, Genomics, Chromothripsis, SVS, Breast cancer, HRD, BRCA2, OGM, BRCA1, Drug resistance, Medical imaging

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.

Key Points: 
  • HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
  • The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
  • Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
  • “We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.